Conflicts of interest and clinical drug trials -- impact of the pharmaceutical industry and the impingement on the integrity of medical science
Numerous studies have addressed the subject of the extent and consequences of financial ties between pharmaceutical companies, academic institutions and clinical researchers. Based on these reports, guidelines for the management of conflicts of interest have been developed which give priority to the patients' welfare on all levels of interaction between doctors and industrial sponsors. The declaration of potential conflicts of interest and strict adherence to guidelines are mandatory to retain the physicians' credibility, reputation, and professional autonomy. Enhanced transparency in the conduct and analysis of clinical trials should be regarded as a valuable tool to uncover and avoid undue influence on clinical trials and derived prescription recommendations.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen - 103(2009), 3 vom: 15., Seite 149-54 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Interessenkonflikte und Arzneimittelstudien -- Einfluss der pharmazeutischen Industrie und daraus resultierende Gefahren für die Integrität der medizinischen Wissenschaft |
|---|
| Beteiligte Personen: |
Ludwig, Wolf-Dieter [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 28.07.2009 Date Revised 11.11.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM189554592 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM189554592 | ||
| 003 | DE-627 | ||
| 005 | 20231223183833.0 | ||
| 007 | tu | ||
| 008 | 231223s2009 xx ||||| 00| ||ger c | ||
| 028 | 5 | 2 | |a pubmed24n0632.xml |
| 035 | |a (DE-627)NLM189554592 | ||
| 035 | |a (NLM)19554889 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Ludwig, Wolf-Dieter |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Conflicts of interest and clinical drug trials -- impact of the pharmaceutical industry and the impingement on the integrity of medical science |
| 246 | 3 | 3 | |a Interessenkonflikte und Arzneimittelstudien -- Einfluss der pharmazeutischen Industrie und daraus resultierende Gefahren für die Integrität der medizinischen Wissenschaft |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2009 | ||
| 500 | |a Date Revised 11.11.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Numerous studies have addressed the subject of the extent and consequences of financial ties between pharmaceutical companies, academic institutions and clinical researchers. Based on these reports, guidelines for the management of conflicts of interest have been developed which give priority to the patients' welfare on all levels of interaction between doctors and industrial sponsors. The declaration of potential conflicts of interest and strict adherence to guidelines are mandatory to retain the physicians' credibility, reputation, and professional autonomy. Enhanced transparency in the conduct and analysis of clinical trials should be regarded as a valuable tool to uncover and avoid undue influence on clinical trials and derived prescription recommendations | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Hildebrandt, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Schott, Gisela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen |d 2008 |g 103(2009), 3 vom: 15., Seite 149-54 |w (DE-627)NLM184447119 |x 2212-0289 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2009 |g number:3 |g day:15 |g pages:149-54 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2009 |e 3 |b 15 |h 149-54 | ||